-
LIV Golf to lay off majority of staff
-
US designates UK-based Palestine Action as foreign 'terrorist group'
-
How narwhal 'scientists' track Arctic warming
-
'Rocky Horror Picture Show' star Tim Curry dead at 80
-
Iran says US sanctions will achieve nothing
-
American Moll wins women's pole vault at Zurich city event
-
Essential Dolly: five key Parton songs
-
As Canada takes on US tariffs, what's behind the David and Goliath fight?
-
Veteran promoter Warren says it's Joshua's job to agree Fury fight
-
UEFA 'likely' to drop threat to boycott FIFA tournaments: source
-
Ex-champ Wawrinka gets last-minute wildcard to US Open
-
US disrupts platforms allegedly used by Chinese hackers
-
Brennan blasts to Vuelta stage five victory, Pogacar holds lead
-
The foreign tourists missing in Nepal's flash floods
-
What could change for US teens on Instagram and Facebook
-
Hundreds missing after Nepal-Tibet flood kills 98
-
Meta, US states agree $16.7 bn settlement in landmark teen safety case
-
CIA director was on 'semi-routine' mission in Moscow: Trump
-
'Point of no return' if Israel-Hamas truce fails: US envoy to Gaza board
-
Aldeguer switches to Rossi's VR46 for next season
-
Barcelona holding out hope for Alvarez as Atletico resist sale
-
Rent TRON Energy and Reduce USDT Fees : TronBid Expands Marketplace
-
Werro basks in new status, shelves world record talk
-
Pakistan captain Babar Azam returns against England '90 percent fit'
-
Bill Gates warns world unprepared for AI upheaval
-
Stocks mixed as oil drops, inflation stays high
-
Prince Harry and family arrive back in Britain: UK media
-
Improving standards transform pole vault as spectacle, says Duplantis
-
German plan for sugar tax on Coke Zero fizzles out
-
India close in on win despite Sri Lanka fightback in second Test
-
Deadly flood hits Nepal-Tibet border, hundreds unaccounted for
-
MEXC TradFi Gala Concludes With Over 170,000 Registrations and $4.3 Billion in Daily Trading Volume
-
Tongue says Root has left England in no doubt over conduct standards
-
Olympic skating champion Liu to skip new season
-
Flags lowered across US for country music legend Dolly Parton
-
Benfica sign midfielder Palhinha from Bayern
-
Stocks gain as oil drops on Mideast hopes
-
Flick says Barca may go without striker as Atletico resist Alvarez sale
-
Bouaddi joins Man City for Premier League teenage record £85.6 mn
-
Too hot to incubate: Nile crocodiles hatch on their own in French reserve
-
Reclusive Hungarian author Peter Nadas dies aged 83
-
Spurs closing in on Man City's Marmoush after signing Savio
-
Man City sign Lille's Bouaddi for 100 mn euros
-
Celtic count the cost of Champions League flop
-
Sooriyabandara, Mendis lead Sri Lanka fightback after follow-on
-
Lebanon accuses Israel of burning forest, farmland in south
-
With ropes and chants, thousands move Japanese castle
-
Nepal floods at China border kill 8, cause 'major casualties' in Tibet
-
Zurich Diamond League: five events to watch
-
France eases cow diets as cheesemakers sweat
Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2026
DORADO, PUERTO RICO / ACCESS Newswire / March 17, 2026 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the quarter ended January 31, 2026 were approximately $2.3 million, a decrease of approximately $0.2 million when compared to the same period last year. Net income for the quarter ended January 31, 2026 was $32,860, an improvement of $24,324 when compared to the same quarter last year.
"We entered this fiscal year focused on executing the strategic priorities established over the past several quarters-sharpening our service portfolio, reinforcing operational alignment, and concentrating on the markets where our capabilities create the most value. We are encouraged by the progress made in improving operational efficiency, which allowed us to deliver a modest profit compared to a slight loss in the same period last year. As we look ahead, we will continue strengthening client relationships, maintaining disciplined cost management, and aligning our organization with the areas of greatest opportunity. We remain confident that these efforts position us well to build momentum and deliver long term value to our shareholders," said Mr. Sanchez, Chief Executive Officer.
About Pharma-Bio Serv, Inc.
Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life science professionals, quality assurance managers and directors.
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this earnings announcement. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this earnings announcement, forward-looking statements are inherently subject to significant business risks, economic uncertainties, and competitive uncertainties, and other factors, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's Annual Report on Form 10-K for the year ended October 31, 2025, and in its other filings with the Securities and Exchange Commission, which filings are available at www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.
Company Contact:
Pedro J. Lasanta
Chief Financial Officer
787 278 2709
SOURCE: Pharma-Bio Serv Inc.
View the original press release on ACCESS Newswire
M.O.Allen--AT